• BAPTA-AM (B4758): Protocol and QC Guide

  2026-08-19

  BAPTA-AM (SKU B4758) is a cell-permeable calcium chelator for experimentally lowering intracellular free Ca²⁺ and testing calcium-dependent responses. It is suited to controlled cellular and biochemical workflows, but results should be interpreted with vehicle, calcium, magnesium, viability, and potassium-channel controls rather than as direct evidence of therapeutic efficacy.

• Leucomycin: From Biosynthesis to Assay Design

  2026-08-19

  Leucomycin and kitasamycin offer a powerful bridge between macrolide pharmacology and Streptomyces biosynthesis. This article presents an evidence-driven framework for connecting precursor flux, translational inhibition, resistance profiling, and assay interpretation.

• Anlotinib Hydrochloride: Mechanism & Research Use

  2026-08-18

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that suppresses VEGFR2, PDGFRβ, and FGFR1 signaling in angiogenesis models. Its nanomolar pathway activity, oral pharmacokinetic profile, and case-report evidence support cancer research applications, while clinical translation remains context-dependent.

• Angiotensin 1/2 (2-7): Assay Design Guide

  2026-08-18

  Explore how the Angiotensin 1/2 (2-7) peptide can be used to design fragment-resolved studies of renin-angiotensin signaling, blood pressure biology, and spike–receptor binding. This guide emphasizes assay controls, sample handling, and the experimental implications of recent peptide-binding evidence.

• MK-1775: From Checkpoint Biology to Translation

  2026-08-17

  A translational framework for using MK-1775, a selective Wee1 kinase inhibitor, to connect G2 checkpoint biology with rigorous in vitro response measurement, combination strategy, and preclinical decision-making.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-17

  Masitinib (AB1010), SKU A2942, provides dossier-defined inhibition of KIT, PDGFRα, and PDGFRβ for targeted kinase and mast-cell workflows. It is best suited to DMSO-based research and should not be selected for aqueous or ethanol-based protocols, broad-spectrum kinase screens, or experiments requiring paper-specific validation that is not available here.

• Cy7 NHS ester: Practical Labeling Guide

  2026-08-16

  Cy7 NHS ester (SKU A8109) is a sulfonated, water-soluble protein labeling dye for attaching near-infrared fluorescence to accessible amino groups in proteins and peptides. It is suited to aqueous biomolecule conjugation and near-infrared fluorescent imaging, but not to targets without suitable amino groups or long-term storage of prepared dye solutions.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-08-15

  The 1992 reference study showed that imidazoline α2-adrenergic receptor antagonists increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than simply by blocking α2-adrenoceptors. Its combination of islet perifusion, 86Rb efflux, and whole-cell patch-clamp experiments provides a mechanistic framework for interpreting Tolazoline in islet function research.

• Viral RIPK3 Degradation Controls Inflammation

  2026-08-14

  Liu and colleagues identified a viral inducer of RIPK3 degradation, or vIRD, that couples the orthopoxvirus SCF ubiquitin machinery to proteasomal removal of a central necroptosis kinase. Their genetic and infection studies show that vIRD is not simply an immune-evasion factor: by suppressing RIPK3–MLKL signaling, it reshapes viral replication, inflammation, and disease severity in a virus- and host-dependent manner.

• How Kinase Inhibitors Promote p38α Dephosphorylation

  2026-08-14

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by stabilizing a phosphatase-compatible activation-loop conformation. This structural and kinetic framework suggests a route to designing inhibitors that suppress signaling through coordinated control of kinase activity and kinase deactivation.

• Nebivolol Hydrochloride: Reading Negative Data

  2026-08-13

  Nebivolol hydrochloride is a potent β1-adrenoceptor antagonist for receptor-focused cardiovascular studies. This article explains how a drug-sensitized yeast mTOR assay can sharpen target interpretation without converting a negative TOR result into an unsupported claim.

• Gemcitabine HCl in MRI-Guided Tumor Studies

  2026-08-13

  Gemcitabine HCl combines mechanism-driven cytotoxicity with longitudinal tumor measurement, enabling researchers to connect DNA replication inhibition to anatomical treatment response. Pairing cell-based assays with multianimal MRI creates a practical, scalable workflow for pancreatic cancer models and preclinical treatment studies.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-12

  Masitinib (AB1010, SKU A2942) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for focused KIT and PDGFRα/β studies, including cancer biology, mastocytosis research, and inflammatory cell assays. It is not a suitable choice for broad-spectrum kinase profiling or workflows requiring aqueous or ethanol solubility.

• SB525334 for TGF-beta1 Receptor Research

  2026-08-12

  SB525334 provides a selective way to interrogate ALK5-driven Smad2/3 signaling in fibrosis, renal disease, and wound-repair models. This guide connects practical cell-based workflows with the bone-transport diabetic foot ulcer study, while emphasizing controls, exposure limits, and context-dependent interpretation.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-11

  Masitinib (AB1010) provides a DMSO-compatible tool for selective KIT, PDGFRα, and PDGFRβ inhibition in cell-based and biochemical research. It is appropriate for targeted cancer, mastocytosis, and mast-cell studies, but not for aqueous or ethanol-based assays or experiments requiring broad-spectrum kinase inhibition.

15308 records 1/1021 page Next 12345 下5页 Last page